Biotech raises $20 million; East Brunswick hotel acquired; Soligenix expands licensing.
Roka Bioscience Inc. announced Thursday it recently completed a Series C round of equity financing, raising $20 million in new capital. The financing brings the total amount raised to $57.2 million since the Warren-based company’s formation in September 2009. The investor syndicate included participation from all existing investors including OrbiMed Advisors, New Enterprise Associates Inc., TPG Biotech and Gen-Probe Inc.
The Lightstone Group announced Thursday it has closed on a senior mortgage acquisition secured by the Holiday Inn Express Hotel & Suites Tower Center, in East Brunswick. Lightstone purchased the note for approximately $5.6 million through its Lightstone Value Plus Real Estate Investment Trust.
Soligenix Inc., in Princeton, announced Thursday the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals Inc. for the development and commercialization of orBec into the European territory. As part of the amended agreement, Sigma–Tau has made a $5 million upfront payment to Soligenix. In addition, Sigma–Tau will make additional payments to Soligenix totaling $11 million, subject to the achievement of certain milestones.